Table 2.
Association between VEGF and eNOS polymorphisms and progression–free survival (PFS)
| Polymorphisms | CT + B | CT | ||||
|---|---|---|---|---|---|---|
| Median PFS (95% CI) | HR (95% CI) | P* | Median PFS (95% CI) | HR (95% CI) | P* | |
| VEGF −2578 | ||||||
| AA | 9.3 (3.1–12.5) | 1.18 (0.72–1.93) | 9.1 (7.8–11.4) | 1.27 (0.81–1.99) | ||
| CC/CA | 10.4 (8.9–12.4) | 1.00 | 0.515 | 9.0 (7.8–10.3) | 1.00 | 0.304 |
| VEGF −1498 | ||||||
| CC | 9.1 (6.4–12.5) | 1.30 (0.81–2.11) | 9.1 (7.8–11.4) | 1.21 (0.77–1.90) | ||
| TT/CT | 10.7 (9.1–12.4) | 1.00 | 0.277 | 9.0 (7.8–10.3) | 1.00 | 0.406 |
| VEGF −1154 | ||||||
| AA | 11.5 (2.3–18.5) | 1.09 (0.54–2.21) | 9.1 (3.1–12.2) | 1.74 (0.89–3.38) | ||
| GA/GG | 10.3 (8.3–12.9) | 1.00 | 0.808 | 9.6 (8.9–11.3) | 1.00 | 0.105 |
| VEGF −634 | ||||||
| GC | 9.1 (7.5–11.3) | 1.21 (0.81–1.82) | 9.0 (7.0–10.3) | 1.14 (0.77–1.68) | ||
| GG/CC | 11.7 (9.1–12.9) | 1.00 | 0.356 | 9.1 (8.0–11.3) | 1.00 | 0.513 |
| VEGF +936 | ||||||
| TT | 7.8 (1.7–9.1) | 3.63 (1.09–12.14) | 28.0 (–) | 0.34 (0.04–2.76) | ||
| CT/CC | 10.2 (9.0–12.4) | 1.00 | 0.036 | 9.1 (8.3–10.2) | 1.00 | 0.311 |
| eNOS +894 | ||||||
| GT | 8.9 (6.8–10.2) | 1.70 (1.12–2.60) | 9.0 (7.4–9.6) | 1.06 (0.73–1.54) | ||
| GG/TT | 11.9 (9.6–14.1) | 1.00 | 0.013 | 10.0 (8.3–11.4) | 1.00 | 0.773 |
| eNOS VNTR | ||||||
| 4bb | 10.9 (9.1–12.9) | 0.63 (0.41–0.96) | 9.1 (8.3–10.3) | 1.09 (0.69–1.74) | ||
| 4ab/4aa | 9.1 (6.2–11.3) | 1.00 | 0.034 | 8.9 (6.1–11.6) | 1.00 | 0.708 |
| eNOS −786 | ||||||
| CC | 12.7 (4.7–14.3) | 0.90 (0.52–1.56) | 8.9 (4.2–11.5) | 1.17 (0.68–2.03) | ||
| CT/TT | 9.6 (8.5–11.3) | 1.00 | 0.709 | 9.1 (8.6–10.3) | 1.00 | 0.572 |
*Adjusted for CT (FOLFOX4/FOLFIRI), gender, age, KRAS status, tumor localization (rectum/colon).